Impact Biomedicines, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Impact Biomedicines, Inc.
Private Company Edition: Immunocore’s $130m round kicked off a series of $100m-plus venture capital deals, including financings for Xilio, Akouos and Pliant. Also, VC investment in cell and gene therapies surged in 2019 and MPM launched two funds with $126 for early cancer research.
Investors in Impact Biosciences, which sold the selective JAK2 inhibitor to Celgene for $1.1bn up front, could double their money with milestone fees based on fedratinib's approval.
The latest drug development news and highlights from our US FDA Performance Tracker.
Celgene's quarterly earnings call was all about reassuring investors that its products and pipeline will deliver the full value of the company's acquisition by Bristol-Myers after the deal closes in the third quarter.
- Other Names / Subsidiaries
- Celege Corporation